SEC Form 4 · accession 0001127602-18-010570

Elevance Health, Inc. · ELV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

John E Gallina

Officer — EVP & Chief Financial Officer

Period of report

Mar 5, 2018

Accepted (ET)

Mar 7, 2018 · 4:35 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001156039

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 5, 2018	G	2,448	$0.00	D	22,139	D
Common Stock	Mar 5, 2018	M	3,948	$61.88	A	26,087	D
Common Stock	Mar 5, 2018	M	3,921	$131.80	A	30,008	D
Common Stock	Mar 5, 2018	M	6,466	$89.44	A	36,474	D
Common Stock	Mar 5, 2018	M	4,036	$132.51	A	40,510	D
Common Stock^F2	Mar 5, 2018	S	15,104	$229.19	D	25,406	D
Common Stock^F3	Mar 5, 2018	S	5,372	$230.44	D	20,034	D
Common Stock^F4	Mar 5, 2018	S	4,100	$231.29	D	15,934	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F5	$61.88	Mar 5, 2018	M	3,948	D	—	Mar 1, 2020	Common Stock	3,948	0	D
Employee Stock Option (Right to Buy)^F6	$131.80	Mar 5, 2018	M	3,921	D	—	Mar 1, 2026	Common Stock	3,921	1,962	D
Employee Stock Option (Right to Buy)^F7	$89.44	Mar 5, 2018	M	6,466	D	—	Mar 3, 2021	Common Stock	6,466	0	D
Employee Stock Option (Right to Buy)^F8	$132.51	Mar 5, 2018	M	4,036	D	—	Jun 1, 2026	Common Stock	4,036	4,038	D

Explanation of responses

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2017.
F2This transaction was executed in multiple trades at prices ranging from $229.00 to $229.98. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $230.00 to $230.97. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4This transaction was executed in multiple trades at prices ranging from $231.01 to $231.83. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5The option, representing a right to purchase a total of 11,843 shares, is exercisable in one installment of 1,973 shares and five semi-annual installments of 1,974 shares each beginning on September 1, 2013, which is the six-month anniversary of the date on which the option was granted.
F6The option, representing a right to purchase a total of 5,883 shares, is exercisable in three semi-annual installments of 980 shares each and three semi-annual installments of 981 shares each beginning on September 1, 2016, which is the six-month anniversary of the date on which the option was granted.
F7The option, representing a right to purchase a total of 9,698 shares, is exercisable in four semi-annual installments of 1,616 shares each and two semi-annual installments of 1,617 shares each beginning on September 3, 2014, which is the six-month anniversary of the date on which the option was granted.
F8The option represents a right to purchase a total of 8,074 shares, is exercisable in two installments of 1,345 shares each and four installments of 1,346 shares each, beginning on December 1, 2016, which is the six-month anniversary of the option grant date.